Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_assertion type Assertion NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_head.
- NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_assertion description "[KRAS mutation is present in 30%-50% of colorectal cancers and is associated with the inefficacy of anti-epidermal growth factor receptor therapy, while the impact of KRAS on survival is seldom discussed.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_provenance.
- NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_assertion evidence source_evidence_literature NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_provenance.
- NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_assertion SIO_000772 25713893 NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_provenance.
- NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_assertion wasDerivedFrom befree-2016 NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_provenance.
- NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_assertion wasGeneratedBy ECO_0000203 NP1266222.RAhaLso2Qj4G-R0wtWbCk5RCu01ODvqWlKN5K5mUK23zw130_provenance.